Home Healthcare Hemophilia A Treatment Market
hemophilia a treatment market

Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs (Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy) and By Regions]: Market Estimate & Forecast, 2016 - 2022

  • Published Date: Feb 2018
  • Pages: 100
  • Format: PDF
  • Report ID: PM1107
  • Base Year: 2017
  • Historical Data: 2015-2016

Report Content

The Marketed Therapies covered in the forecast from 2016-2022 are:

  • Afstyla Sales Forecast-2016-2022
  • Eloctate Sales Forecast-2016-2022
  • Hemlibra Sales Forecast-2016-2022
  • Kogenate FS Sales Forecast-2016-2022
  • Kovaltry Sales Forecast-2016-2022
  • Nuwiq Sales Forecast-2016-2022
  • Obizur Sales Forecast-2016-2022

The Major Indications in Hemophilia A Treatment Therapy area:

  • Prophylaxis-Market Forecast 2016-2022
  • On-demand therapy-Market Forecast 2016-2022
  • Inhibitor therapy- Market Forecast 2016-2022

The Forecast of Hemophilia A Treatment Market by G7 Countries (2016-2022)

  • United States- Market Forecast (2016-2022)
  • Germany- Market Forecast (2016-2022)
  • France-Market Forecast (2016-2022)
  • Italy- Market Forecast (2016-2022)
  • Spain- Market Forecast (2016-2022)
  • United Kingdom- Market Forecast (2016-2022)
  • Japan- Market Forecast (2016-2022)

 Leading Companies investigated in the Report are

  • CSL Behring
  • Shire
  • Bayer
  • Biogen
  • Genentech
  • Bioverativ
  • Alnylam Pharmaceuticals
  • Sanofi (Genzyme)
  • BioMarin Pharmaceutical
  • Hoffmann-La Roche
  • Sinocelltech Ltd.
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
  • Octapharma
  • LFB USA, Inc.
  • Novo Nordisk A/S
  • Pfizer

 

 

Polaris Market Research
Hemophilia A Treatment Market Size, Share - Industry Report 2017-2022